Cyproheptadine Hydrochloride NDC 17856-0504

NDC codes

FDA NDC Directory

Product NDC (as listed)17856-0504Labeler and product segments. Claims need a package NDC.

Product NDC at billing width17856-0504Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
17856-0504-1	17856050401	120 SYRINGE in 1 CASE (17856-0504-1) / 2.5 mL in 1 SYRINGEMarketed from Apr 30, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cyproheptadine Hydrochloride
Generic name (nonproprietary): cyproheptadine hydrochloride
Active ingredients: Cyproheptadine hydrochloride — 2 mg/5mL
Dosage form: Syrup
Route: Oral
Labeler: Atlantic Biological Corp.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 040668
Marketing start: Jul 10, 2006
Listing expires: Dec 31, 2027
Identifiers: Product ID 17856-0504_50b39d04-bda7-78bd-e063-6294a90a490dSPL ID 50b39d04-bda7-78bd-e063-6294a90a490dSPL set ID 50b3abc0-d86a-e8f5-e063-6394a90ad25eRxCUI 866021UNII NJ82J0F8QC

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N417856050401 followed by a unit qualifier and the quantity

Package 17856-0504-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 30, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 040668

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 040668
Product	Strength	Form · route	Labeler	Product NDC
Cyproheptadine Hydrochloride	Cyproheptadine hydrochloride 2 mg/5mL	SyrupOral	Rising Pharma Holdings, Inc.	64980-504